Optogenetic Therapy With UGX-201 in Advanced Nonsyndromic Retinitis Pigmentosa: Safety and Efficacy From an Exploratory Clinical Trial

医学 临床试验 光遗传学 视网膜炎 失明 肿瘤科 内科学 眼科 梅德林 眼病 临床研究
作者
Xue Han,Zhaoqi Zhu,Ziyue Song,Gaoqin Liu,Xue Yin,Jiawei Shen,Junfa Xue,Kai Wu,Xueting Luo,Zhiping Cui,Peirong Lu
出处
期刊:American Journal of Ophthalmology [Elsevier BV]
卷期号:287: 222-236 被引量:3
标识
DOI:10.1016/j.ajo.2026.03.042
摘要

OBJECTIVE: To evaluate the safety, tolerability, and preliminary efficacy of a single intravitreal injection of UGX-201, an optogenetic therapy utilizing an adeno-associated virus 2 type 7m8 variant to deliver a recombinant chimeric opsin to retinal ganglion cells, in advanced nonsyndromic retinitis pigmentosa (RP) patients. DESIGN: An investigator-initiated, open-label, nonrandomized, single-center trial (ChiCTR2200062174). PARTICIPANTS: Nine patients with advanced nonsyndromic RP were enrolled and stratified into two cohorts by visual function: six with light perception (LP) cohort and three with no LP (NLP) cohort. METHODS: vg/eye was administered in one eye per participant. All participants were followed up for at least 52 weeks and underwent comprehensive ophthalmic and systemic safety assessments along with visual structure and function examinations. MAIN OUTCOME MEASURES: The primary endpoint was safety, including adverse events (AEs), serious AEs, and treatment-related AEs over 52 weeks. Secondary endpoints included changes from baseline in best-corrected visual acuity, full-field stimulus threshold testing, and National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) scores through 52-week follow-up period. RESULTS: No serious ocular or systemic AEs occurred during the 52-week follow-up period. In the LP cohort, mean best-corrected visual acuity in the treated eyes assessed by Freiburg Visual Acuity and Contrast Test showed an improvement of 0.30 logMAR at Week 52. One participant exhibited substantial improvement in full-field stimulus threshold testing. The total composite score of the NEI VFQ-25 in LP cohort increased by 3.72 points at Week 52 from that at baseline. In the NLP cohort, all three participants restored LP in the treated eyes at Week 2, Week 4, and Week 24, respectively. Among them, two still maintained LP at Week 52 (end of study). CONCLUSIONS: UGX-201 exhibited a favorable safety profile and was well-tolerated in patients with advanced nonsyndromic RP. Sustained, meaningful visual acuity gains were observed in both LP and NLP cohorts, irrespective of baseline visual function status. These findings underscore the potential of UGX-201 as a first-in-class mutation-independent treatment option for advanced nonsyndromic RP.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
Wuyuan50完成签到,获得积分10
刚刚
三岁完成签到,获得积分10
刚刚
xjh的应助被岳鑫采纳,获得10
刚刚
小龙完成签到,获得积分10
1秒前
2秒前
完美清炎完成签到,获得积分20
2秒前
2秒前
涤宇发布了新的文献求助10
3秒前
3秒前
大模型的应助被余思采纳,获得10
3秒前
3秒前
4秒前
5秒前
Owen的应助被n11采纳,获得10
5秒前
复杂千亦完成签到,获得积分10
5秒前
晕仔完成签到,获得积分10
5秒前
清脆的橘子完成签到,获得积分10
5秒前
叶迎完成签到,获得积分10
6秒前
英姑的应助被leahlin采纳,获得10
6秒前
kong发布了新的文献求助10
6秒前
Hiker发布了新的文献求助10
6秒前
自信诗桃发布了新的文献求助10
7秒前
7秒前
所所的应助被赵22222222采纳,获得10
7秒前
天天快乐的应助被wjw采纳,获得10
7秒前
慈祥的翠梅完成签到,获得积分10
8秒前
烟色晚空完成签到,获得积分10
8秒前
tang发布了新的文献求助30
9秒前
9秒前
9秒前
9秒前
9秒前
张兵发布了新的文献求助10
9秒前
无极微光的应助被墩子采纳,获得20
10秒前
10秒前
CodeCraft的应助被igiss采纳,获得10
10秒前
11秒前
求求你们帮帮我完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166